|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LOX |
Gene summary for LOX |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LOX | Gene ID | 4015 |
| Gene name | lysyl oxidase | |
| Gene Alias | AAT10 | |
| Cytomap | 5q23.1 | |
| Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | B7ZAJ4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4015 | LOX | P4T-E | Human | Esophagus | ESCC | 3.52e-03 | 3.03e-01 | 0.1323 |
| 4015 | LOX | P8T-E | Human | Esophagus | ESCC | 7.98e-04 | 2.02e-01 | 0.0889 |
| 4015 | LOX | P16T-E | Human | Esophagus | ESCC | 2.51e-10 | 3.41e-01 | 0.1153 |
| 4015 | LOX | P17T-E | Human | Esophagus | ESCC | 1.22e-04 | 5.42e-01 | 0.1278 |
| 4015 | LOX | P23T-E | Human | Esophagus | ESCC | 8.95e-05 | 2.66e-01 | 0.108 |
| 4015 | LOX | P32T-E | Human | Esophagus | ESCC | 7.80e-22 | 9.89e-01 | 0.1666 |
| 4015 | LOX | P37T-E | Human | Esophagus | ESCC | 9.32e-18 | 6.36e-01 | 0.1371 |
| 4015 | LOX | P42T-E | Human | Esophagus | ESCC | 9.84e-07 | 3.99e-01 | 0.1175 |
| 4015 | LOX | P44T-E | Human | Esophagus | ESCC | 2.72e-04 | 6.69e-01 | 0.1096 |
| 4015 | LOX | P52T-E | Human | Esophagus | ESCC | 1.68e-10 | 5.54e-01 | 0.1555 |
| 4015 | LOX | P61T-E | Human | Esophagus | ESCC | 3.95e-07 | 2.81e-01 | 0.099 |
| 4015 | LOX | P62T-E | Human | Esophagus | ESCC | 1.12e-04 | 2.69e-01 | 0.1302 |
| 4015 | LOX | P74T-E | Human | Esophagus | ESCC | 1.39e-02 | 1.59e-01 | 0.1479 |
| 4015 | LOX | P76T-E | Human | Esophagus | ESCC | 1.70e-17 | 7.18e-01 | 0.1207 |
| 4015 | LOX | P89T-E | Human | Esophagus | ESCC | 1.46e-19 | 1.93e+00 | 0.1752 |
| 4015 | LOX | P91T-E | Human | Esophagus | ESCC | 1.63e-05 | 1.14e+00 | 0.1828 |
| 4015 | LOX | P130T-E | Human | Esophagus | ESCC | 2.01e-15 | 5.56e-01 | 0.1676 |
| 4015 | LOX | C21 | Human | Oral cavity | OSCC | 1.02e-16 | 8.01e-01 | 0.2678 |
| 4015 | LOX | C30 | Human | Oral cavity | OSCC | 8.45e-06 | 6.01e-01 | 0.3055 |
| 4015 | LOX | C43 | Human | Oral cavity | OSCC | 1.19e-30 | 5.57e-01 | 0.1704 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
| GO:002240710 | Cervix | CC | regulation of cell-cell adhesion | 103/2311 | 448/18723 | 1.78e-10 | 2.87e-08 | 103 |
| GO:004578510 | Cervix | CC | positive regulation of cell adhesion | 101/2311 | 437/18723 | 1.96e-10 | 3.08e-08 | 101 |
| GO:000697910 | Cervix | CC | response to oxidative stress | 102/2311 | 446/18723 | 2.99e-10 | 4.36e-08 | 102 |
| GO:00506737 | Cervix | CC | epithelial cell proliferation | 98/2311 | 437/18723 | 2.01e-09 | 2.15e-07 | 98 |
| GO:00321035 | Cervix | CC | positive regulation of response to external stimulus | 95/2311 | 427/18723 | 5.44e-09 | 5.03e-07 | 95 |
| GO:00071598 | Cervix | CC | leukocyte cell-cell adhesion | 85/2311 | 371/18723 | 8.27e-09 | 7.07e-07 | 85 |
| GO:00603267 | Cervix | CC | cell chemotaxis | 73/2311 | 310/18723 | 2.82e-08 | 1.96e-06 | 73 |
| GO:19030378 | Cervix | CC | regulation of leukocyte cell-cell adhesion | 77/2311 | 336/18723 | 4.08e-08 | 2.54e-06 | 77 |
| GO:006219710 | Cervix | CC | cellular response to chemical stress | 76/2311 | 337/18723 | 1.01e-07 | 5.25e-06 | 76 |
| GO:00506787 | Cervix | CC | regulation of epithelial cell proliferation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
| GO:00305957 | Cervix | CC | leukocyte chemotaxis | 57/2311 | 230/18723 | 1.48e-07 | 7.07e-06 | 57 |
| GO:19030349 | Cervix | CC | regulation of response to wounding | 44/2311 | 167/18723 | 6.33e-07 | 2.31e-05 | 44 |
| GO:190589710 | Cervix | CC | regulation of response to endoplasmic reticulum stress | 27/2311 | 82/18723 | 9.24e-07 | 3.25e-05 | 27 |
| GO:00509007 | Cervix | CC | leukocyte migration | 78/2311 | 369/18723 | 1.09e-06 | 3.80e-05 | 78 |
| GO:00988699 | Cervix | CC | cellular oxidant detoxification | 30/2311 | 101/18723 | 2.72e-06 | 7.93e-05 | 30 |
| GO:003459910 | Cervix | CC | cellular response to oxidative stress | 63/2311 | 288/18723 | 3.58e-06 | 9.50e-05 | 63 |
| GO:00454445 | Cervix | CC | fat cell differentiation | 53/2311 | 229/18723 | 3.72e-06 | 9.75e-05 | 53 |
| GO:003497610 | Cervix | CC | response to endoplasmic reticulum stress | 57/2311 | 256/18723 | 5.81e-06 | 1.42e-04 | 57 |
| GO:190357310 | Cervix | CC | negative regulation of response to endoplasmic reticulum stress | 17/2311 | 44/18723 | 8.57e-06 | 1.97e-04 | 17 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LOX | insertion | In_Frame_Ins | novel | c.899_900insAAGATATCTCTGTTTTTTCACCTGTGAAACCATTCCTTCCTTCTGTTT | p.Glu300_Phe301insArgTyrLeuCysPhePheThrCysGluThrIleProSerPheCysLeu | p.E300_F301insRYLCFFTCETIPSFCL | P28300 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| LOX | SNV | Missense_Mutation | novel | c.1202G>A | p.Arg401His | p.R401H | P28300 | protein_coding | tolerated(0.66) | benign(0.07) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| LOX | SNV | Missense_Mutation | c.1010N>A | p.Arg337Gln | p.R337Q | P28300 | protein_coding | deleterious(0.02) | probably_damaging(0.98) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| LOX | SNV | Missense_Mutation | c.49G>A | p.Ala17Thr | p.A17T | P28300 | protein_coding | tolerated(0.37) | benign(0) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
| LOX | SNV | Missense_Mutation | novel | c.761N>C | p.Val254Ala | p.V254A | P28300 | protein_coding | tolerated(0.52) | benign(0.048) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| LOX | SNV | Missense_Mutation | c.19G>A | p.Val7Met | p.V7M | P28300 | protein_coding | tolerated(0.08) | benign(0.003) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| LOX | SNV | Missense_Mutation | c.842N>A | p.Arg281Gln | p.R281Q | P28300 | protein_coding | deleterious(0.02) | possibly_damaging(0.821) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| LOX | SNV | Missense_Mutation | rs566461481 | c.364N>T | p.Arg122Cys | p.R122C | P28300 | protein_coding | deleterious(0.01) | benign(0.001) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LOX | SNV | Missense_Mutation | c.76G>A | p.Ala26Thr | p.A26T | P28300 | protein_coding | tolerated(0.61) | benign(0) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| LOX | SNV | Missense_Mutation | c.842N>A | p.Arg281Gln | p.R281Q | P28300 | protein_coding | deleterious(0.02) | possibly_damaging(0.821) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4015 | LOX | ENZYME, DRUGGABLE GENOME | inhibitor | 385612244 | ||
| 4015 | LOX | ENZYME, DRUGGABLE GENOME | inhibitor | 385612245 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |